A citation-based method for searching scientific literature

Erin A Bohula, Robert P Giugliano, Christopher P Cannon, Jing Zhou, Sabina A Murphy, Jennifer A White, Andrew M Tershakovec, Michael A Blazing, Eugene Braunwald. Circulation 2015
Times Cited: 186







List of co-cited articles
1180 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
Paul M Ridker, Brendan M Everett, Tom Thuren, Jean G MacFadyen, William H Chang, Christie Ballantyne, Francisco Fonseca, Jose Nicolau, Wolfgang Koenig, Stefan D Anker,[...]. N Engl J Med 2017
63

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Paul M Ridker, Eleanor Danielson, Francisco A H Fonseca, Jacques Genest, Antonio M Gotto, John J P Kastelein, Wolfgang Koenig, Peter Libby, Alberto J Lorenzatti, Jean G MacFadyen,[...]. N Engl J Med 2008
47

C-reactive protein levels and outcomes after statin therapy.
Paul M Ridker, Christopher P Cannon, David Morrow, Nader Rifai, Lynda M Rose, Carolyn H McCabe, Marc A Pfeffer, Eugene Braunwald. N Engl J Med 2005
41

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Marc S Sabatine, Robert P Giugliano, Anthony C Keech, Narimon Honarpour, Stephen D Wiviott, Sabina A Murphy, Julia F Kuder, Huei Wang, Thomas Liu, Scott M Wasserman,[...]. N Engl J Med 2017
33

Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.
Paul M Ridker, Brendan M Everett, Aruna Pradhan, Jean G MacFadyen, Daniel H Solomon, Elaine Zaharris, Virak Mam, Ahmed Hasan, Yves Rosenberg, Erin Iturriaga,[...]. N Engl J Med 2019
526
33

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Christopher P Cannon, Michael A Blazing, Robert P Giugliano, Amy McCagg, Jennifer A White, Pierre Theroux, Harald Darius, Basil S Lewis, Ton Oude Ophuis, J Wouter Jukema,[...]. N Engl J Med 2015
26


Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
Paul M Ridker, Eleanor Danielson, Francisco Ah Fonseca, Jacques Genest, Antonio M Gotto, John Jp Kastelein, Wolfgang Koenig, Peter Libby, Alberto J Lorenzatti, Jean G Macfadyen,[...]. Lancet 2009
730
23

Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.
Jean-Claude Tardif, Simon Kouz, David D Waters, Olivier F Bertrand, Rafael Diaz, Aldo P Maggioni, Fausto J Pinto, Reda Ibrahim, Habib Gamra, Ghassan S Kiwan,[...]. N Engl J Med 2019
819
22

Low-dose colchicine for secondary prevention of cardiovascular disease.
Stefan M Nidorf, John W Eikelboom, Charley A Budgeon, Peter L Thompson. J Am Coll Cardiol 2013
468
21

Inflammatory and Cholesterol Risk in the FOURIER Trial.
Erin A Bohula, Robert P Giugliano, Lawrence A Leiter, Subodh Verma, Jeong-Gun Park, Peter S Sever, Armando Lira Pineda, Narimon Honarpour, Huei Wang, Sabina A Murphy,[...]. Circulation 2018
121
21

Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.
Aruna D Pradhan, Aaron W Aday, Lynda M Rose, Paul M Ridker. Circulation 2018
89
23

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Gregory G Schwartz, P Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Jay M Edelberg, Shaun G Goodman, Corinne Hanotin, Robert A Harrington,[...]. N Engl J Med 2018
21

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.
P M Ridker, N Rifai, M Clearfield, J R Downs, S E Weis, J S Miles, A M Gotto. N Engl J Med 2001
19

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
C Baigent, L Blackwell, J Emberson, L E Holland, C Reith, N Bhala, R Peto, E H Barnes, A Keech, J Simes,[...]. Lancet 2010
18

NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals.
Peter Duewell, Hajime Kono, Katey J Rayner, Cherilyn M Sirois, Gregory Vladimer, Franz G Bauernfeind, George S Abela, Luigi Franchi, Gabriel Nuñez, Max Schnurr,[...]. Nature 2010
18



Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
P M Ridker, M Cushman, M J Stampfer, R P Tracy, C H Hennekens. N Engl J Med 1997
16


Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
Steven E Nissen, E Murat Tuzcu, Paul Schoenhagen, Tim Crowe, William J Sasiela, John Tsai, John Orazem, Raymond D Magorien, Charles O'Shaughnessy, Peter Ganz. N Engl J Med 2005
15


Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Christopher P Cannon, Eugene Braunwald, Carolyn H McCabe, Daniel J Rader, Jean L Rouleau, Rene Belder, Steven V Joyal, Karen A Hill, Marc A Pfeffer, Allan M Skene. N Engl J Med 2004
14

C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis.
Stephen Kaptoge, Emanuele Di Angelantonio, Gordon Lowe, Mark B Pepys, Simon G Thompson, Rory Collins, John Danesh. Lancet 2010
14


Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.
Michelle L O'Donoghue, Eugene Braunwald, Harvey D White, Mary Ann Lukas, Elizabeth Tarka, P Gabriel Steg, Judith S Hochman, Christoph Bode, Aldo P Maggioni, KyungAh Im,[...]. JAMA 2014
287
13

Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial.
David A Morrow, James A de Lemos, Marc S Sabatine, Stephen D Wiviott, Michael A Blazing, Amy Shui, Nader Rifai, Robert M Califf, Eugene Braunwald. Circulation 2006
234
12

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis.
Daniel I Swerdlow, Michael V Holmes, Karoline B Kuchenbaecker, Jorgen E L Engmann, Tina Shah, Reecha Sofat, Yiran Guo, Christina Chung, Anne Peasey, Roman Pfister,[...]. Lancet 2012
637
12

Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).
Paul M Ridker, Peter Libby, Jean G MacFadyen, Tom Thuren, Christie Ballantyne, Francisco Fonseca, Wolfgang Koenig, Hiroaki Shimokawa, Brendan M Everett, Robert J Glynn. Eur Heart J 2018
219
12

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Deepak L Bhatt, P Gabriel Steg, Michael Miller, Eliot A Brinton, Terry A Jacobson, Steven B Ketchum, Ralph T Doyle, Rebecca A Juliano, Lixia Jiao, Craig Granowitz,[...]. N Engl J Med 2019
12

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
François Mach, Colin Baigent, Alberico L Catapano, Konstantinos C Koskinas, Manuela Casula, Lina Badimon, M John Chapman, Guy G De Backer, Victoria Delgado, Brian A Ference,[...]. Eur Heart J 2020
12

Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.
Michael G Silverman, Brian A Ference, Kyungah Im, Stephen D Wiviott, Robert P Giugliano, Scott M Grundy, Eugene Braunwald, Marc S Sabatine. JAMA 2016
576
11

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.
Alberico L Catapano, Ian Graham, Guy De Backer, Olov Wiklund, M John Chapman, Heinz Drexel, Arno W Hoes, Catriona S Jennings, Ulf Landmesser, Terje R Pedersen,[...]. Eur Heart J 2016
11


Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.
Robert P Giugliano, Terje R Pedersen, Jeong-Gun Park, Gaetano M De Ferrari, Zbigniew A Gaciong, Richard Ceska, Kalman Toth, Ioanna Gouni-Berthold, Jose Lopez-Miranda, François Schiele,[...]. Lancet 2017
308
10

Darapladib for preventing ischemic events in stable coronary heart disease.
Harvey D White, Claes Held, Ralph Stewart, Elizabeth Tarka, Rebekkah Brown, Richard Y Davies, Andrzej Budaj, Robert A Harrington, P Gabriel Steg, Diego Ardissino,[...]. N Engl J Med 2014
353
10


Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.
Brian A Ference, Henry N Ginsberg, Ian Graham, Kausik K Ray, Chris J Packard, Eric Bruckert, Robert A Hegele, Ronald M Krauss, Frederick J Raal, Heribert Schunkert,[...]. Eur Heart J 2017
10


Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial.
Ola Kleveland, Gabor Kunszt, Marte Bratlie, Thor Ueland, Kaspar Broch, Espen Holte, Annika E Michelsen, Bjørn Bendz, Brage H Amundsen, Terje Espevik,[...]. Eur Heart J 2016
168
10

How Common Is Residual Inflammatory Risk?
Paul M Ridker. Circ Res 2017
66
15

Colchicine in Patients with Chronic Coronary Disease.
Stefan M Nidorf, Aernoud T L Fiolet, Arend Mosterd, John W Eikelboom, Astrid Schut, Tjerk S J Opstal, Salem H K The, Xiao-Fang Xu, Mark A Ireland, Timo Lenderink,[...]. N Engl J Med 2020
384
10

Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome: A CT Coronary Angiography Study.
Kaivan Vaidya, Clare Arnott, Gonzalo J Martínez, Bernard Ng, Samuel McCormack, David R Sullivan, David S Celermajer, Sanjay Patel. JACC Cardiovasc Imaging 2018
116
9

Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management.
Erik S Stroes, Paul D Thompson, Alberto Corsini, Georgirene D Vladutiu, Frederick J Raal, Kausik K Ray, Michael Roden, Evan Stein, Lale Tokgözoğlu, Børge G Nordestgaard,[...]. Eur Heart J 2015
715
9

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
C Baigent, A Keech, P M Kearney, L Blackwell, G Buck, C Pollicino, A Kirby, T Sourjina, R Peto, R Collins,[...]. Lancet 2005
9

Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial.
Michelle L O'Donoghue, Ruchira Glaser, Matthew A Cavender, Philip E Aylward, Marc P Bonaca, Andrzej Budaj, Richard Y Davies, Mikael Dellborg, Keith A A Fox, Jorge Antonio T Gutierrez,[...]. JAMA 2016
144
9

The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation.
Gonzalo J Martínez, David S Celermajer, Sanjay Patel. Atherosclerosis 2018
119
9

The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina.
G Liuzzo, L M Biasucci, J R Gallimore, R L Grillo, A G Rebuzzi, M B Pepys, A Maseri. N Engl J Med 1994
9

The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study.
Allison C Morton, Alexander M K Rothman, John P Greenwood, Julian Gunn, Alex Chase, Bernard Clarke, Alistair S Hall, Keith Fox, Claire Foley, Winston Banya,[...]. Eur Heart J 2015
169
9



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.